Global Validation of PREVENT & SCORE2 Risk Equations

By Azon Vault On May 6, 2026

Introduction: A Massive Global Study

Recent research set out to test two leading cardiovascular risk tools—PREVENT and SCORE2—on an unprecedented scale of 6.4\u00a0million people spanning every continent.

Why PREVENT and SCORE2 Matter

These equations help clinicians estimate a patient’s 10‑year risk of heart disease, guiding prevention strategies and treatment intensity.

Study Design and Population

The analysis pooled data from 150 cohort studies, electronic health records, and national registries. Participants were aged 40‑85, with diverse ethnicity, socioeconomic status, and baseline health.

Data Sources and Scale

Together the datasets covered urban, rural, high‑income, and low‑income settings, providing a true multinational snapshot of cardiovascular risk.

Performance Metrics Across Regions

Researchers evaluated calibration, discrimination, and clinical usefulness using AUROC, Brier score, and net reclassification improvement.

Key Findings

Calibration: Both equations performed well in high‑income regions but tended to over‑predict risk in low‑ and middle‑income cohorts.

Discrimination: AUROC values ranged from 0.78 to 0.85, showing strong predictive power but modest variation by geography.

Reclassification: Adding traditional risk factors modestly improved models, underscoring the need for localized risk factors.

Implications for Practice and Policy

Clinicians can consider using PREVENT and SCORE2 as complementary tools, but should adjust thresholds according to regional disease patterns.

Public health planners may leverage the study’s data to allocate screening resources more efficiently across populations.

Limitations and Future Directions

The study relied on existing observational data, which may miss undiagnosed cases. Future work will explore machine‑learning enhancements and integration of biomarkers for finer granularity.

Conclusion

Multinational validation of PREVENT and SCORE2 across 6.4\u00a0million individuals confirms their utility while highlighting the importance of region‑specific calibration. This evidence paves the way for more personalized, globally informed cardiovascular prevention.